RedHill Biopharma (RDHL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RedHill Biopharma Ltd. has announced encouraging results from in vivo studies of opaganib, a novel oral treatment with potential for obesity and Type 2 diabetes management. The drug has shown effectiveness in weight control and glucose tolerance in high-fat diet models, highlighting its therapeutic promise. Opaganib, which also has antiviral and anti-inflammatory properties, is part of ongoing U.S. government collaborations and could address a market projected to reach $100 billion by 2034.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.